SR ONE CAPITAL MANAGEMENT, LP
13F Reported Value
ⓘ$1.0B
Holdings
15
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
SR ONE CAPITAL MANAGEMENT, LP disclosed 15 positions worth $1.0B in its Form 13F-HR for Q2 2026, led by $MANE (Veradermics, Inc) at 28.4% of the equity portfolio, followed by $ZBIO and $CRSP. During the quarter the fund opened 3 new positions and exited 2 — including a new stake in $AVLN and a full exit from $ACLX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from SR ONE CAPITAL MANAGEMENT, LP’s Form 13F-HR filing with the SEC under CIK 1910264.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$295.3M2,401,868 sh - 7.4#2,945
Quality
$127.9M5,037,854 sh - 9.7#2,915
Quality
$111.2M2,038,763 sh - —
Quality
$108.9M3,308,649 sh - —
Quality
$94.4M6,526,476 sh - —
Quality
$71.0M3,794,883 sh - 7.1
Quality
$55.2M1,959,896 sh - —
Quality
$50.0M4,615,384 sh - —
Quality
$42.2M1,563,966 sh - 20.3
Quality
$32.1M4,012,903 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Veradermics, Inc$MANE | — | $295.3M | 2,401,868 |
 Zenas BioPharma, Inc.$ZBIO | 7.4#2,945 | $127.9M | 5,037,854 |
 CRISPR Therapeutics AG$CRSP | 9.7#2,915 | $111.2M | 2,038,763 |
 Avalyn Pharma Inc.$AVLN | — | $108.9M | 3,308,649 |
 Design Therapeutics, Inc.$DSGN | — | $94.4M | 6,526,476 |
 Odyssey Therapeutics, Inc.$ODTX | — | $71.0M | 3,794,883 |
 ALUMIS INC.$ALMS | 7.1 | $55.2M | 1,959,896 |
 Oric Pharmaceuticals, Inc.$ORIC | — | $50.0M | 4,615,384 |
 Mineralys Therapeutics, Inc.$MLYS | — | $42.2M | 1,563,966 |
 ARS Pharmaceuticals, Inc.$SPRY | 20.3 | $32.1M | 4,012,903 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SR ONE CAPITAL MANAGEMENT, LP's 15 positions.
Showing top 10 of 15 holdings.
Sector Allocation
Healthcare
$1.0B
Full Holdings — SR ONE CAPITAL MANAGEMENT, LP (Q2 2026)
All 15 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MANE | Veradermics, Inc | $295.3M | 28.4% | +0% | — |
| 2 | $ZBIO | Zenas BioPharma, Inc. | $127.9M | 12.3% | +0% | 7.4 |
| 3 | $CRSP | CRISPR Therapeutics AG | $111.2M | 10.7% | +0% | 9.7 |
| 4 | $AVLN | Avalyn Pharma Inc. | $108.9M | 10.5% | NEW | — |
| 5 | $DSGN | Design Therapeutics, Inc. | $94.4M | 9.1% | +0% | — |
| 6 | $ODTX | Odyssey Therapeutics, Inc. | $71.0M | 6.8% | NEW | — |
| 7 | $ALMS | ALUMIS INC. | $55.2M | 5.3% | +0% | 7.1 |
| 8 | $ORIC | Oric Pharmaceuticals, Inc. | $50.0M | 4.8% | +2% | — |
| 9 | $MLYS | Mineralys Therapeutics, Inc. | $42.2M | 4.1% | +0% | — |
| 10 | $SPRY | ARS Pharmaceuticals, Inc. | $32.1M | 3.1% | +0% | 20.3 |
| 11 |  $MOBI | Mobia Medical, Inc. | $26.6M | 2.6% | NEW | — |
| 12 |  $NKTX | Nkarta, Inc. | $9.4M | 0.9% | +0% | — |
| 13 |  $OCS | Oculis Holding AG | $8.9M | 0.9% | +0% | — |
| 14 |  $RARE | Ultragenyx Pharmaceutical Inc. | $4.6M | 0.4% | +0% | 34.2 |
| 15 |  $ENGN | enGene Therapeutics Inc. | $1.3M | 0.1% | +0% | — |
New Positions (3)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SR ONE CAPITAL MANAGEMENT, LP including:
Track SR ONE CAPITAL MANAGEMENT, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SR ONE CAPITAL MANAGEMENT, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SR ONE CAPITAL MANAGEMENT, LP
13F Pro is an AI hedge fund tracker and stock research platform. For SR ONE CAPITAL MANAGEMENT, LP (SEC CIK: 1910264), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SR ONE CAPITAL MANAGEMENT, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.